

KURZPROTOKOLL
Checkmate CA209-817

Öffentlicher Titel	Nivolumab und Ipilimumab bei fortgeschrittenem Nicht-kleinzelligem Lungenkrebs
Wissenschaftl. Titel	A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants With Advanced Malignancies.
Kurztitel	Checkmate CA209-817
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, offen/unverblindet, Pharma-Studie, zweiarmig
Studienphase	Phase III/IV
Erkrankung	Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Zweitlinie oder höher Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - Erstlinie
Einschlusskriterien	<ul style="list-style-type: none">- Histologically confirmed Stage 4 or recurrent non-small cell lung cancer- Eastern Cooperative Oncology Group (ECOG) score 0-1 (Physically able to carry out light housework or office work through to being fully active as you were before cancer)- No prior systemic anticancer therapy (including EGFR and ALK inhibitors)- Tissue or Programmed death-ligand 1 (PD-L1) results available
Ausschlusskriterien	<ul style="list-style-type: none">- Untreated brain metastases- An active malignancy that requires concurrent intervention- Active, known or suspected autoimmune disease- Carcinomatous meningitis, which means there is inflammation of the covering of the brain, caused by cancer
Alter	18 Jahre und älter
Prüfzentren	Krankenhaus Nordwest GmbH (Rekrutierung beendet) Klinik für Onkologie und Hämatologie Steinbacher Hohl 2-26 60488 Frankfurt am Main Manuela Padberg Tel: 069 7601-4558 Fax: 069 7601-3655 padberg.manuela@khnw.de
Sponsor	Bristol-Myers Squibb
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT02869789 EudraCT 2016-002621-10